stockrow
Friday 6 November 2026
Export CLNN’s income statement to Excel — free account
Clene Inc.
CLNN Healthcare Biotechnology
Clene Inc.’s revenue for fiscal 2025 (year ended December 2025) was $200,000.00, down 41.5% from fiscal 2024.
- Revenue
- +273.3%
- EPS
- +135.2%
- Free cash flow
- −16.6%
- Total debt
- −60.3%
Quarter to September 2026, against a year earlier
3.85
0.12
−3.02%
Follow CLNN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
3 | 2 | 3 | 2 |
+8 more TTM periods Free account |
| 197.50% | 237.15% | 281.87% | 197.91% | ||
| (120.65%) | (174.99%) | (142.67%) | (115.13%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(1,118.68%) | (256.98%) | (280.19%) | (619.63%) | |
Average Days of Receivables |
65.95 | 79.67 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.27) | (1.29) | (1.55) | (1.89) | |
Free Cash Flow |
(16.62) | (15.95) | (18.06) | (18.59) | |
Capital Expenditures |
(0.09) | (0.04) | — | (0.04) | |
| Other line items | |||||
Cash ROIC |
(1,242.38%) | (497.60%) | (520.25%) | (1,633.30%) | |
Accounts Receivable Turnover |
2.56 | 3.68 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.09 | 0.10 | 0.00 | 0.07 | |
Inventory Turnover |
1.86 | 1.67 | 0.00 | 1.50 | |
Average Days of Payables |
3,311.89 | 4,297.22 | 0.00 | 4,121.27 | |
Days of Inventory on Hand |
157.53 | 139.23 | 0.00 | 170.95 | |
Tax Rate |
(0.57) | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
5,777.31% | 6,505.58% | 9,596.27% | 7,005.50% | |
Selling, General and Administrative Expense of Revenue |
3,219.75% | 3,996.45% | 6,208.96% | 4,614.50% | |
Share Based Compensation of Revenue |
2,015.13% | 2,751.27% | 4,288.81% | 3,191.00% | |
Interest Coverage |
(7.34) | (7.13) | (7.35) | (8.61) | |
Operating CF/Net income |
0.62 | 0.40 | 0.54 | 0.71 | |
Depreciation/Fixed assets |
0.28 | 0.27 | 0.26 | 0.25 | |
Capex/Depreciation |
(0.06) | (0.03) | 0.00 | (0.03) | |
Revenue per Share |
0.02 | 0.02 | 0.01 | 0.02 | |
Operating CF per Share |
(1.26) | (1.28) | (1.55) | (1.88) | |
Capex per Share |
(0.01) | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.38 | 0.21 | 0.00 | 0.21 |
Columns are period end dates · fundamentals updated 6 Nov 2026